Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Other financing activities (2018 - 2025)

Harvard Bioscience (HBIO) has disclosed Other financing activities for 10 consecutive years, with $3.1 million as the latest value for Q4 2025.

Quarterly Other financing activities rose 2983.33% to $3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, up 1374.55% year-over-year, with the annual reading at $3.8 million for FY2025, 2280.12% up from the prior year.
Other financing activities for Q4 2025 was $3.1 million at Harvard Bioscience, up from $24000.0 in the prior quarter.
The five-year high for Other financing activities was $3.1 million in Q4 2025, with the low at -$451000.0 in Q3 2023.
Average Other financing activities over 5 years is $570277.8, with a median of $217500.0 recorded in 2022.
The sharpest move saw Other financing activities plummeted 216.54% in 2023, then soared 2983.33% in 2025.
Over 5 years, Other financing activities stood at $861000.0 in 2021, then plummeted by 46.46% to $461000.0 in 2022, then soared by 447.29% to $2.5 million in 2023, then tumbled by 95.96% to $102000.0 in 2024, then skyrocketed by 2983.33% to $3.1 million in 2025.
According to Business Quant data, Other financing activities over the past three periods came in at $3.1 million, $24000.0, and $75000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.